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1
ESTERS OF 3'-DEAMINODOXORUBICIN AND
LIPOSOMAL COMPOSITIONS THEREOF
2
DETAILED DESCRIPTION OF A SPECIFIC
EMBODIMENT
Compoundsin accordance with the present invention
The present application is a continuation of applica- 5 havethe general formula
tion Ser. No. 07/145,271 filed Jan. 19, 1988, nowaban-
doned.
FIELD OF THE INVENTION
The present invention relates to derivatives of dox-
orubicin, liposomal formulations thereof, and methods
of using such derivatives and formulations to inhibit
neoplastic cell growth.
BACKGROUNDOF THE INVENTION
Doxorubicin is knownto be an affective anti-neoplas-
tic agent. Someofits derivatives also are knownto have
such activity. However, undesired side effects like car-
diotoxicity and bone marrow toxicity limit its use. Sev-
eral investigators have shown previously that liposome
encapsulation of doxorubicin results in enhanced antitu-
moractivity against liver tumors and decreased cardi-
otoxicity. However, because doxorubicin is highly hy-
drophilic, the encapsulation and stability of liposomal
doxorubicin are poor, and as a result al] known attempts
to obtain a satisfactory liposomal doxorubicin formula-
tion have failed.
A compound which has the antitumor activity of
doxorubicin but is more amenable to liposome encapsu-
lation would havesignificant therapeutic advantages. A
long standing need exists for such a compound.
SUMMARYOF THE INVENTION





and pharmaceutically acceptable salts thereof. R can be
an acyl group having from 1 to 20 carbon atoms.
Compoundsin accordance with the present invention
can be readily encapsulated in liposomes. The resulting
liposomesare highly stable, and in tests conducted so
far have demonstrated greater activity in vivo than
doxorubicinitself.
The compounds and liposomal! formulations of the
present invention are useful in methods of inhibiting
neoplastic cell growth. Such methods involve adminis-
tration of an effective amount of the compoundorlipo-
some-encapsulated composition,usually with a pharma-
















where R can be an acy! group having from 1 to 20
carbon atoms. Pharmaceutically acceptable salts of the
above described compoundsare also included in the
present invention. R is preferably aliphatic. For exam-
ple, it cam be —CO(CH?2)nCH3, where n is from 0-18.
Long chain acyl groups such as lauroyl, myristoyl,
palmitoyl, and stearoyl should be particularly useful.
Manyother acyl groups should be suitable as well.
The following is an example of how a compoundin
accordance with the present invention, 7-0-(2,6-
dideoxy-a-L-lyxo-hexopyranosy])-14-0-palmitoyla-
driamycinone, has been synthesized. Substrate 7-0(2,6-
dideoxy-a-L-lyxo-hexopyranosyl)adriamycinone was
prepared in five steps by the procedure described by D.
Horton, W. Priebe, O. Varela, J. Antibiotics 37 (8),
853-858, (1984).
The synthesis as described in that paper is based on an
intermediate, 14-O-tert-Butyldimethylsilyl-7-O-(3,4-di-
O-acetyl-2,6-dideoxy -a-L-lyxo-hexopyranosyl)






To a solution of adriamycinone (0.35g, 0.85 mmol) in
DMF(2 ml), imidazole (0.15g, 2.2mmol) and tert-butyl-
chlorodimethylsilane (0.13g, 0.86mmol) were added,
and the mixture wasstirred at 25° C. After 2 hours, the
same quantites as before of imidazole and the silylating
reagent were added. The mixture wasstirred for 1 hour
at room temperature and then diluted with CH2Cl2 (200
ml), washed with 5% HCl (50 ml) and H2O (50 mi), and
dried over magnesium sulfate containing approximately
0.5 g of sodiurn carbonate. The mixture wasfiltered and
the filtrate evaporated. The residue crystallized upon
addition of absolute EtOH; yield 0.27 g. The mother
liquors were evaporated and the residue purified by
column chromatography onsilica gel (30 g), with 9:1,
toluene-acetone as eluant. Fractions containing the
product of Rf 0.51 (3:1, toluene-acetone) were pooled
and evaporated. The 14-silylated adriamycinone (0.1 g)
precipitated from an ethereal solution upon addition of






This compound was prepared by two different proce- 5
dures.
(a) A mixture of compound A (541.2 mg, 1.02 mmol),
yellow mercuric oxide (807 mg), mercuric bromide (55
mg) and powdered molecular sieve 4 A(~2g) in
CH2Ch (30 ml) wasstirred for 0.5 hour at 25° C., and 10
then a solution of its chloride, prepared from 426 mg
(2mmol) of 3,4-di-O-acetyl-L-fucal in CH2Cl2, was
added. The mixture was stirred overnight at 25° C.,
diluted with 50 ml of CH2Ch, and filtered through
Celite. The filtrate was washed with 10% aqueous po- 15
tassium iodide (230 ml) and twice with an excess of
H20. The organic layer was dried with magnesium
sulfate, filtered, and evaporated under diminished pres-
sure, affording a red oi! that crystallized from acetone-




Compound C 0.44 g, 0.7 mmol) was dissolved in dry 25
DMF(2 ml). To this solution were added imidazole
(0.12 g, 1.76 mmol) and tert-butylchlorodimethylsilane
(0.137 g, 0.91 mmol) and the mixture wasstirred for 20
hours at room temperature. TLC monitoring showed
some Starting material remaining, and so additional 30
silylating reagent (0.06 g, 0.4 mmol) was added. After
an additional 2 hours, the starting material had disap-
peared. The mixture was poured into H2O (30 ml) and
extracted with CH2Cl, (100 ml, twice). The extract was
washed with 5% HCI (50 ml), H2O (50 ml) and 10% 35
aqueous sodium hydrogencarbonate, dried over magne-
sium sulfate, and evaporated. The residue was dissolved
tn CH2Clz (2 ml) and reprecipitated byaddition of hex-
ane; yield 0.44 g (84.6%).
14-O0-tert-Butyldimethylsilyl-7-O-(2,6-dideoxy-a-L-lyx-
o-hexopyranosyl)adriamycinone (Compound D)
Compound B (0.40 g, 0.54 mmol) was dissolved in
MeOH(30 ml) andthe solution wasstirred for 1 hour at
25° C. with 25% sodium methoxide in MeOH (0.31 ml,
1.35mmol). The mixture was made neutral by the addi-
tion of dry ice and evaporated to 15 ml under dimin-
ished pressure. The solution was diluted with CH2Cl2
(200 ml), extracted with H2O (50 ml, twice), drived
over magnesium sulfate, and evaporated. The residue
was dissolved in a small volume of hot MeOH,and the
productprecipitated upon cooling; yield 0.31g (88%) of
a solid that wassufficiently pure for the next step of the
synthesis. Further purification could be achieved by
dissolving the solid in the minimal amount of CH2Cl2 55




Compound D (0.20g, 0.3mmol) was dissolved in a
mixture of CH2Cl2 (10 ml), oxolane (20 ml) and pyridine
(0.2 ml), and 1M tetrabutylammonium fluoride (0.45 ml,
0.45 mmol) was added. After 1 hour, the mixture was
diluted with 400 ml of CH2Cl2 and extracted with 50-ml 65
portions of saturated NaCl, 5% HCl, H2O and 10%
sodium hydrogencarbonate. The extract was dried over





tallized from a concentrated solution in CH2Cl; yield
86 mg. Dilution of the mother liquors with ether gave




driamycinone (108.0 mg, 0.195 mmol) prepared as de-
scribed above was dissolved in dry pyridine (3 ml).
Palmitoyl chloride (92 mg, 0.335 mmol) (available from
Pfaltz and Bauer Inc.) was added, and the reaction was
stirred at room temperature and monitored by TLC
(toluene-acetone 1:1). TLC was performed on pre-
coated plastic sheets (0.22 mm) and glass plates
(0.25mm)ofsilica gel 60F-254 (E. Merck, Darmstadt,
GFR). Components were detected by spraying the
plates with 2 M sulfuric acid, with subsequent heating.
After 90 minutes, another portion of palmitoy! chlo-
ride (55 mg, 0.20 mmol) was added. The reaction was
stopped after 2 hours by pouring the solution into wa-
ter, followed by extraction with dichloromethane. The
organic layer was subsequently washed with a 10%
solution of hydrochloric acid, a saturated solution of
sodium bicarbonate, and then twice with water. The
solution was then dried over sodium sulfate overnight.
Filtration and evaporation under diminished pressureat
50° C. led to formation of red thickoil.
Purification by column chromotographyonsilica gel
60 (230-400 mesh) (E. Merck, Darmstadt, GFR) (22 g).
with 2:1 (50 ml), and then 1:1, toluene-acetoneas eluant
gave 7-Q-(2,6-dideoxy-a-L-lyxo-hexopyranosy])-14-O-
palmitoyladriamycinone as a red solid; yield 59 mg
(32.4%). 1H and 13C NMRspectra were recorded at 200
MHz and 50 MHz, respectively, with an IBM
NR/200AF spectrometer: !3C NMR (50 MHz, CDC]s)
206.4 (C-13), 186.9, 186.5 (C-5, 12), 173.2 (C=0-ester),
161.0 (C-4), 156.2, 155.7 (C-6, 11), 135.6, 135.4, 133.9,
133.7 (C-2, 6a, 10a, 12a), 120.8 (C-4a), 119.7 (C-1), 118.4
(C-3), 111.5, 111.3, (C-5a, 11a), 101.1 (C-1'), 77.3 (C-9),
71.0, 69.4, 67.1, 65.7 (x2) * (C-3', 4’, 5’, 7, 14), 56.6
(OMe), 35.2, 33.9, 33.7, 32.5, 31.9, 29.6 (intensity >x5),
29.4, 29.3, 29.1, 24.9, 24.7, 22.6 (C-8, 10, 2’, CHpalmit-
oyl chain), 16.7 (C-6’), 14.1 (CH3 -palmitoy] chain).
*Overlapping signals of CH and CH2 groups. Confirmed by refocussed
INEPTexperiment.
The compound prepared as described above, referred
to as WR-1, was encapsulated in multilamellar lipo-
somes by mixing in a chloroform solution dimyristoy}-
phosphatidyl choline, dimyristoylphosphatidyl glyc-
erol, and WR-1 at a weight ratio of 10.5:4.5:1. The
chloroform was evaporated in a rotary evaporator and
a dried lipid film containing the lipids and WR-1 was
obtained. Multilamellar liposomes were formed by add-
ing normalsaline (1 ml/mg WR-1)to the driedlipid film
and hand-shaking for 1 minute.
Liposomal-WR-1 can also be prepared in a lyophi-
lized powder by dissolving the lipids and WR-1 in t-
butanol and freeze-drying. Liposomes are formed upon
reconstitution of the powder with normal saline and
vortexing for 1 minute.
Liposomes were sized in a Coulter Counter. Vesicle
size ranged from | to 34m. Encapsulation of WR-1 in
the lipid vesicles was assessed by measuring the amount
of drug in the supernatant and thepellet after centrifu-
gation of the liposomal-WR-1 preparation. The drug
was measured by UV spectrophotometry at 250 nm.
The encapsulation efficiency was greater than 99%.
Stability of the lipid vesicles was assessed by measuring
5,132,290
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the amount of WR-1 released after 14 days at 4° C. The
stability was found to be greater than 99%.
The antitumoractivity of liposomal-WR-1 wastested
against L1210 leukemia and liver metastases of M5076
reticulosarcoma in vivo. BDF1 mice were inoculated
intraperitoneally on day 0 with 1 million L1210 cells.
Treatment wasgiven as a single injection intraperitone-
ally on day 1. Liposomal-WR-1 at whatis believed to be
the optimal dose (60 mg/kg) resulted in a % T/C (mean
survival of treated animals/mean survival of control
animals x 100) of more than 600 with more than 50% of
the treated animals alive on day 60. The mean survival
of controls was 8 days. Doxorubicin at the optimal dose
of 10 mg/kg resulted in a %T/C of 187 with only 1/6
animals alive on day 60.
C57 BL/G mice wereinoculated with 2x 104 M5076
cells intravenously on day 0. Treatment was given on
days 4, 8, and 12 intravenously. Liposomal WR-1 at a
dose of 20 mg/kg on days 4, 8, and 12 resulted in a %
T/C of 175, while doxorubicin at the optimal dose of 8
mg/kg on days 4,8, and 12 resulted in a % T/C of 128.
Liposomal formulations in accordance with the pres-
ent invention include fatty substances such as phospho-
lipids, optionally cholesterol, and the anthracyclines
described above. The formulations preferably include
anthracycline and phospholipid in a ratio ranging from 2
about 1 to 10 to about 1 to 30, with a 1 to 15 ratio being
most preferred.
In addition to the phospholipidslisted in the preced-
ing example for the formulation of the liposome vesi-
































The presently preferred liposome formulation com-
prises dimyristoylphosphatidylglycerol and dimyris-
toylphosphatidylcholine, preferably in a ratio between
about | to 10 and about 10 to 1. The most preferredratio
at this time is about 3 to 7.
The liposomes of the present invention may be mul-
tilamellar, unilamellar or have an undefined lamellar










ing liposome-encapsulated compounds in accordance
with the present invention and a pharmaceutically ac-
ceptable carrier or diluent maybe used for the therapy
of disease conditions such as cancer.
Methods in accordance with the present invention
comprise administering to a host an effective amount of
the compounds or compositions described above. The
administering step is preferably parenteral and by intra-
venous, intraarterial, intramuscular, intralymphatic,
intraperitoneal, subcutaneous, intrapleural or intrathe-
cal injection or by topical application or oral dosage.
Such administration is preferably repeated on a timed
schedule, for example twice daily for a period of two
weeks. The treatment may be maintained until tumor
regression or disappearance has been achieved and may
be used in conjunction. with other forms of tumorther-,
apy such as surgery or chemotherapy with different
agents.
The examples and specific description given in this
patent application are intended only to illustrate the
present invention,not to provide an exhaustive descrip-
tion of all possible embodiments of the present inven-
tion. Those skilled in this field would recognize that
modifications could be made to the examples given that
would remain within the scope of the invention.
Weclaim:




or a pharmaceutically acceptable salt thereof, where R
is palmitoyl.





or a pharmaceutically acceptable salt thereof, where R
is palmitoyl, the compound being encapsulated in a
liposome.
3. The composition of claim 2, where the liposome
comprises dimyristoylphosphatidy] choline, dimyris-
toylphosphatidyl glycerol, and a compound having a
formula specified in claim 5, in an approximate weight
ratio of 1.5:4.5:1.
* * €£ & £
 
UNITED STATES PATENT AND TRADEMARKOFFICE
CERTIFICATE OF CORRECTION
PATENT NO. : 5,132,290
DATED : July 21, 1992
INVENTOR(S) : Priebe, et al
It is certified that error appears in the above-indentified patent and that said Letters Patentis hereby
corrected as shown below:
In claim 3, at column 6, line 66, “claim 5" should read --Claim 2--.
- Signed and Sealedthis
Twenty-fourth Day of August, 1993
Attest: WSence Chwt
BRUCE LEHMAN
Altesting Officer Commissioner of Parents and Trademarks  
